Role of CD28null NKG2Dpos T Cells on Human Alloimmune Reactivity T Cell Population
Overview
This is an observational multi-center study to determine whether any single immune monitoring test or a combination of tests obtained in the first 6 months after renal transplantation correlates with acute rejection or graft loss in renal allograft recipients receiving commonly used immunosuppressive.
Full Title of Study: “Role of CD28null NKG2Dpos T Cells on Human Alloimmune Reactivity: An Untargeted T Cell Population” (# 859869783).”
Study Type
- Study Type: Observational
- Study Design
- Study Primary Completion Date: January 2014
Clinical Trial Outcome Measures
Primary Measures
- To document the prevalence and frequencies of CD4+ and CD8+ CD28null/NKG2Dpos T cells at the time of transplantation.
- Time Frame: 6 months
- To test whether CD28null/NKG2Dpos T cells have unique rapid activation properties to allogeneic HLA antigens in vitro
- Time Frame: 6 months
Secondary Measures
- To study the clinical correlations between the frequencies of alloreactive CD28null/NKG2Dpos T cells with kidney graft function and histopathology.
- Time Frame: 6 months
- To test the effects of induction therapy with rabbit anti-thymocyte globulin (ATG) vs. IL-2 receptor blocker antibodies on circulating CD28null/NKG2Dpos T cells.
- Time Frame: 6 months
Participating in This Clinical Trial
Inclusion Criteria
- human kidney transplant recipients – ATG or basiliximab induction therapy Exclusion Criteria:
- induction therapy other than ATG or basiliximab
Gender Eligibility: All
Minimum Age: N/A
Maximum Age: N/A
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- The Cleveland Clinic
- Provider of Information About this Clinical Study
- Sponsor
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.